Amgen, Inc. (AMGN) Message Board
- Reply to
FDA autologous cell ruling is a step in the opposite direction imo
by headsupeyesclosed •1 hour 10 minutes agoJust added more for the long haul!
-
I find it hard to believe that the FDA would rule against surgery using a patients own cells. What about skin grafts, should there be clinical trials for those too?
The rest of the world will totally kick our a s s in this booming area of cosmetics. -
myownhedge does not know the stem cell field very well.
-
Forbes 2011:
In the case of IntelliCell, the company focuses more on producing large amounts of SVF cells from just a small amount of autologous fat cells of about 2 oz. IntelliCell CEO Dr. Steven Victor found a method that allows the use of ultrasonic cavitation to increase the yield of SVF cells. By using the ultrasonic method, Dr. Victor says he turns the 2 oz. of fat into SVF stem cells of between 0.5 billion and 1.4 billion. The process takes just about 30 minutes at IntelliCell’s labs. Doctors then use the SVF cells for treatment of various ailments, from regenerative cosmetic procedures to repairing tissues involving damaged knees, back injuries, migraine headaches, and multiple sclerosis.
“It is very apparent that a person’s fat cells are the best source of stem cells, which are stored inactively in one’s fat tissues, for use in the fast growing field of regenerative medicine,” says Dr. Victor, a practicing dermatologist for more than 20 years. He says IntelliCell’s proprietary process makes the most cells from the least amount of fat more efficiently and less expensive than any other competing products.
A study of IntelliCell’s technology by Millipore, a division of Merck AG of Germany, confirmed that it produced an average of 10 times the number of SVF cells containing adult adipose stem cells from less than which the company believes is used by any of its present competition that use enzymes in their process. The study also showed that the SVF cells produced by IntelliCell contain all of the viable cells that are manufactured by competing technologies that use enzymes, such as Cytori. - Reply to
IntelliCell method is quicker, simpler, cheaper and more efficient than CYTX for stem cell extraction.
by btimnextmicrosoft •Jun 13, 2013 2:39 PMI had there ticker on my list from after researching them over a year ago. Luckily i got in early today, still a long way to go IMO. I would be happy with a 0.20 buyout.
- Reply to
US Supreme Court - Human Genes Cannot Be Patented
by pharmainvestor1998 •Jun 13, 2013 11:16 AMAgree, should see a West blog post about this soon.
-
This competing technology will surely cut into Cytori's market.
Google:
IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology -
Baltbear/captJ/realtruf.......You sound desperate....maybe you can go back in time and file a complaint of some kind.
-
Google:
Easy and Effective Therapy to Restore Sight: Engineered Virus Will Improve Gene Therapy for Blinding Eye Diseases -
BioTime Appoints Henry L. Nordhoff to Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) today announced that Henry L. Nordhoff, former CEO and Chairman of Gen-Probe Inc., has been appointed to its Board of Directors.
"We are pleased to welcome an accomplished healthcare executive of Hank's caliber to BioTime's board," said Alfred D. Kingsley, Chairman of the Board of BioTime. "Hank's 43 years of experience in the pharmaceutical business, including most recently his leadership role in managing impressive growth at Gen-Probe over a 15-year period should prove valuable as BioTime continues to pursue multiple growth opportunities."
"BioTime is a leading company in the emerging field of Regenerative Medicine," said Mr. Nordhoff. "I am pleased to be joining BioTime at this important juncture, as the company moves towards translating a magnificent array of technologies into products, and then introducing those products into the marketplace to alleviate suffering and cure diseases."
Mr. Nordhoff is the former CEO and Chairman of Gen-Probe, Inc., a leading molecular diagnostics company which was acquired in 2012 in an all-cash transaction that valued the company at $3.72 billion. -
Very impressive Board....includes a former FDA Commisioner to boot!
-
Looks like the calm before the storm. This weeks update leading up to Mayo Clinic showcase could be the much needed 4th of July spark.
- Reply to
Biotime sures up 9MIL to advance Cancer program with Cornell Weill
by btimnextmicrosoft •Jun 7, 2013 10:24 PMDr. West nabbed an exclusive license to the SP100 gene....WINNER!
-
My feeling is BTX will buy the remaining Geron cancer ip sometime in 2014.
-
Looking forward to hearing how monies will be allocated
-
5 Yr chart looks like it's ready for another run. September is the big Stem Cell Summit where West will likely introduce multiple IND's, partnerships, Cancer detection update and more. So It's probable there will be a run starting in late Summer IMO.
Get on board...toot toot! -
West said more on hystem...."see you next week."
Leads me to believe there should be new pre-clinical data on the cartilage regen program.Sentiment: Buy
-
Buyout??.... Quite the opposite dummy. Biotime is the company that bought out Hystem, GeneCards, Geron, and soon another. In a few years after Biotime becomes a household name then they will IPO ReCyte, OrthoCyte and OncoCyte. Nice try bozo.
-
It's Spring for Christ sake...some pollen probably flew in through her hospital window!
-
Good overview, I share your excitement, indeed great future here.